NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients.
Fiche publication
Date publication
novembre 2022
Journal
European heart journal open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVIGNES Marie-Dominique, Pr ROSSIGNOL Patrick
Tous les auteurs :
Rossignol P, Duarte K, Bresso E, A Å, Devignes MD, Eriksson N, Girerd N, Glerup R, Jardine AG, Holdaas H, Lamiral Z, Leroy C, Massy Z, März W, Krämer B, Wu PH, Schmieder R, Soveri I, Christensen JH, Svensson M, Zannad F, Fellström B
Lien Pubmed
Résumé
End-stage renal disease (ESRD) treated by chronic hemodialysis (HD) is associated with poor cardiovascular (CV) outcomes, with no available evidence-based therapeutics. A multiplexed proteomic approach may identify new pathophysiological pathways associated with CV outcomes, potentially actionable for precision medicine.
Mots clés
Cardiovascular, Chronic hemodialysis, NT-proBNP, Prognosis, Stem cell factor
Référence
Eur Heart J Open. 2022 11;2(6):oeac069